Literature DB >> 19003763

[Organizing pneumonia--clarithromycin treatment].

Elzbieta Radzikowska1, Elzbieta Wiatr, Dariusz Gawryluk, Renata Langfort, Iwona Bestry, Mariusz Chabowski, Kazimierz Roszkowski.   

Abstract

INTRODUCTION: Organizing pneumonia (OP) is a rare syndrome that has been associated with a variety of underlying factors including infections, collagen vascular diseases, toxic fumes, cancer, drugs and radiotherapy. A cryptogenic form is also observed. OP is a curable disease in the most cases. Steroids are the standard therapy, but other treatment regimens have been used as well.
MATERIAL AND METHODS: In the period from 1999 to 2005, 9 women and 3 men (age range 44-71 years) with OP were selected for the study. There were 9 non-smokers, 2 smokers and 1 ex-smoker. Open lung biopsy was performed in 5 patients, and in 7 patients diagnosis was established on the basis of transbronchial lung biopsy.
RESULTS: Dyspnoea (100%), cough (100%), weakness (100%), fever (83%), loss of weight (83%), sweats (33%) and chest pain (8%) were the most frequently noticed symptoms. Radiographically, all patients had bilateral consolidations with areas of ground glass attenuations. A migratory pattern of these lesions was observed in 9 (75%) patients. In all patients clarithromycin (CLA) in a dose 0.5 g b.i.d was administered. Nine (75%) patients were successfully treated. Complete clinical and radiological remission was obtained after 3 months of CLA therapy in 7 and a partial response in an additional 2 patients, in whom treatment was prolonged to 4 months. During the first month of CLA treatment 3 patients did not respond to the therapy, and prednisone was introduced. The observation period ranged from 30 to 90 months (mean 42 months). Adverse reaction to CLA and relapse did not occur.
CONCLUSIONS: OP can be treated with clarithromycin. It may be an alternative treatment, particularly for patients in good clinical status and in whom the probability of adverse events in the course of corticotherapy is high.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003763

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  6 in total

1.  Organizing pneumonia revisited: insights and uncertainties from a series of 67 patients.

Authors:  A L Vieira; A Vale; N Melo; P Caetano Mota; J M Jesus; R Cunha; S Guimarães; C Souto Moura; A Morais
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.

Authors:  Nicolas Petitpierre; Vincent Cottin; Sylvain Marchand-Adam; Sandrine Hirschi; Dominique Rigaud; Isabelle Court-Fortune; Stéphane Jouneau; Dominique Israël-Biet; Anita Molard; Jean-François Cordier; Romain Lazor
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 3.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

4.  Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.

Authors:  Qun-Li Ding; Dan Lv; Bi-Jiong Wang; Qiao-Li Zhang; Yi-Ming Yu; Shi-Fang Sun; Zhong-Bo Chen; Hong-Ying Ma; Zai-Chun Deng
Journal:  Exp Ther Med       Date:  2015-01-15       Impact factor: 2.447

5.  Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.

Authors:  Elżbieta Radzikowska; Elżbieta Wiatr; Renata Langfort; Iwona Bestry; Agnieszka Skoczylas; Ewa Szczepulska-Wójcik; Dariusz Gawryluk; Piotr Rudziński; Joanna Chorostowska-Wynimko; Kazimierz Roszkowski-Śliż
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Different Responses to Clarithromycin in Patients with Cryptogenic Organizing Pneumonia.

Authors:  Ji Hyun Oh; Dong Jun Oh; So-My Koo; Yang Ki Kim; Ki Up Kim; Hyun Jo Kim; Dong Won Kim; Soo-Taek Uh
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.